

Što možemo naučiti iz obrazaca znanstvenog objavljivanja tijekom pandemije COVID-19

Homolak, Jan

Conference presentation / Izlaganje na skupu

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:759976>

Rights / Prava: [In copyright/Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-05-20**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine](#)
[Digital Repository](#)





Sveučilište u Zagrebu
Medicinski fakultet
Središnja medicinska knjižnica



2021 MICC
Medical Information Conference Croatia

Wolters Kluwer
Health

Ovid

Što možemo naučiti iz obrazaca znanstvenog objavljivanja tijekom pandemije COVID-19?

Jan Homolak
Zavod za Farmakologiju
Medicinski fakultet Sveučilišta u Zagrebu



Homolak, J. & Kodvanj, I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int. J. Antimicrob. Agents 56, 106044 (2020) doi:10.1016/j.ijantimicag.2020.106044.

**Our world is a mess.
A large part of this mess is made of
COVID-19 information.**



- 
- A photograph of a young man with dark hair, wearing red swim trunks, performing a backflip off a wooden dock into a large body of water. He is suspended in mid-air, arms outstretched. The dock has a metal ladder. The water is blue and slightly choppy. In the background, there is a distant shoreline with trees under a blue sky with scattered white clouds.
- **Enormno puno istraživanja**
 - **Kvantiteta > kvaliteta**
 - **Izraziti „obrtaj”**
 - **Podaci u pravilu nedostupni – a s obzirom na (ne)kvalitetu istraživanja su ključni !**

OBRASCI OBJAVLJIVANJA

DOBRI

Dear Dr. Homolak,

Thank you for your submission to the Journal of Medical Virology.

Wiley has signed up to the World Health Organization (WHO) and Wellcome Trust commitment to share research data and findings relevant to the novel coronavirus outbreak. Please find more information here:


<https://wellcome.ac.uk/press-release/sharing-research-data-and-findings-relevant-novel-coronavirus-covid-19-outbreak>

We request your permission to share this relevant submission directly with the WHO. If you approve, we will share this submission directly with the WHO and indicate that this is a preliminary report that has not been peer reviewed. The WHO would only use this submission for research purposes, it will not be put in the public domain and this will not impact the submission or publication process of your article.

We will not share your submission without your approval. Please be in touch with any questions. We look forward to hearing from you.


Kind regards,
Ms. Aarthi Sharma
Journal of Medical Virology
JMV@wiley.com

Homolak, J., Kodvanj, I. & Virág, D. Preliminary analysis of COVID-19 academic information patterns: a call for open science in the times of closed borders. *Scientometrics* 1–15 (2020) doi:10.1007/s11192-020-03587-2.




OBRASCI OBJAVLJIVANJA


DOBRI




Homolak, J., Kodvanj, I. & Virag, D. Preliminary analysis of COVID-19 academic information patterns: a call for open science in the times of closed borders. *Scientometrics* 1–15 (2020) doi:10.1007/s11192-020-03587-2.



OBRASCI OBJAVLJIVANJA



Kodvanj, I., Homolak, J., Virag, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. *bioRxiv* (2020) doi:10.1101/2020.11.23.394577.



OBRASCI OBJAVLJIVANJA


LOŠI I ZLI

COVID 19


NOT COVID-19,
12/19 – 4/2020

12/18 – 4/19

Travel medicine and infectious disease
The Lancet. Respiratory medicine
The Lancet. Public health
The Lancet. Infectious diseases
The Journal of infection
The Journal of hospital infection
Lancet (London, England)
Journal of the American Academy of Dermatology
Journal of microbiology, immunology, and infection
= Wei mian yu gan ran za zhi
Journal of medical virology
Journal of Korean medical science
Journal of clinical medicine
International journal of infectious diseases :
IJID : official publication of the International
Society for Infectious Diseases
International journal of antimicrobial agents



Homolak, J., Kodvanj, I. & Virág, D. Preliminary analysis of COVID-19 academic information patterns: a call for open science in the times of closed borders. *Scientometrics* 1–15 (2020) doi:10.1007/s11192-020-03587-2.



OBRASCI OBJAVLJIVANJA


LOŠI I ZLI

Table 1. Summary of the analysis of the probability of publishing within 120 days since the first preprint version (a subset of preprints deposited till June 29) and time-to-publishing considering the entire observed period (a subset of preprints deposited till 27 September)¹. Effects are expressed as odds ratios (OR).

| Predictors | Published within 120 days | | Published before Nov. 01 | |
|--------------------------|---------------------------|--------|--------------------------|--------|
| | OR (95% CI) | p | OR (95% CI) | p |
| COVID-19 vs Not COVID-19 | 2.04 (1.87 to 2.23) | <0.001 | 1.42 (1.33 to 1.52) | <0.001 |
| bioRxiv vs medRxiv | 1.33 (1.21 to 1.45) | <0.001 | 1.24 (1.17 to 1.32) | <0.001 |
| ≥2 vs 1version | 0.72 (0.66 to 0.78) | <0.001 | 0.90 (0.85 to 0.94) | <0.001 |

¹ Stratified (by preprinting date of the first version) logistic regression was fitted to the probability of being published within 120 days and over the entire observed period.

Kodvanj, I., Homolak, J., Virág, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. bioRxiv (2020) doi:10.1101/2020.11.23.394577.



OBRASCI OBJAVLJIVANJA


LOŠI I ZLI

Table 2. Analysis of submission-to-acceptance time for published preprints (in days)¹.

| Predictors | Estimates (95% CI) | p |
|--------------------------|---------------------------|--------|
| COVID-19 vs Not COVID-19 | -38.67 (-42.39 to -34.96) | <0.001 |
| bioRxiv vs medRxiv | 0.25 (-3.36 to 3.86) | 0.891 |
| ≥2 vs 1 preprint version | 0.96 (-2.00 to 3.91) | 0.526 |

¹ Linear mixed-effects model (submission date specified as a random effect) was fitted to the number of days between the date of receipt by the journal and date of acceptance. Submission to publication time was identified for 421 COVID-19/bioRxiv (median=49 days), 4191 not-COVID-19/bioRxiv (median=95 days), 1032 COVID-19/medRxiv (median=48 days), 423 not-COVID-19/medRxiv preprints (median=97 days).

Kodvanj, I., Homolak, J., Virag, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. bioRxiv (2020) doi:10.1101/2020.11.23.394577.




OBRASCI OBJAVLJIVANJA

LOŠI I ZLI

Table 3. The number of retractions/expressions of concern/corrections identified at Retraction Watch Database (RWD), the total number of PubMed articles, and retraction rates (notices/total number of articles) for COVID-19-related articles and articles related to four other viruses/associated diseases, two research fields (epidemiology, immunology).


| Topic | RWD count ¹ | Pubmed count ² | Retraction rate |
|-----------------|------------------------|---------------------------|-----------------|
| COVID-19 | 36 | 64915 | 0.55‰ |
| Not COVID-19 | 306 | 1428252 | 0.21‰ |
| HIV | 1 | 10453 | 0.10‰ |
| Herpes virus | 3 | 2663 | 1.13‰ |
| Influenza | 0 | 3411 | - |
| Hepatitis virus | 0 | 1321 | - |
| Epidemiology | 6 | 40279 | 0.15‰ |
| Immunology | 8 | 63577 | 0.13‰ |

Kodvanj, I., Homolak, J., Virág, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. bioRxiv (2020) doi:10.1101/2020.11.23.394577.





OBRASCI OBJAVLJIVANJA


LOŠI I ZLI




B




C



Kodvanj, I., Homolak, J., Virág, D. & Trkulja, V. Bibliographic database functionality with respect to missingness of article descriptors and database structure: A case study of the WHO COVID-19 database. [Submitted manuscript] (2020).




RJEŠENJE?



data-against-covid.org

[Sign Up](#) [Log In](#)




You – clinicians, virologists, immunologists – are working around the clock to combat the epidemic. We – machine learners, bioinformaticians, epidemiologists, statisticians – are eager to help. This is the place to post your data and give us tasks: answer your questions, analyze your data, make predictions. Just remember that to help you, we need data. If you're unsure where to begin, take a look at our [FAQ + Guidelines](#).

>List of PIs Supporting this Endeavour

I have data science skills...

RJEŠENJE?



**Rescale, Google Cloud,
and Microsoft Azure to
Accelerate COVID-19
Vaccine with Cloud
Supercomputing**

High performance computing resources immediately available at no cost to engineers, scientists, and researchers fighting COVID-19.

[LEARN MORE](#)

Apply for Cloud Resources

Your Name



Email Address

Organization Name

Research or Initiative

SUBMIT

RJEŠENJE?



PUBPEER
The online journal club



THE PREPRINT SERVER FOR HEALTH SCIENCES

medRxiv

CSH
Cold
Spring
Harbor
Laboratory



BMJ Yale

There are 2 articles on this page with PubPeer comments

x

**THE TROUBLE WITH
MOST OF US IS THAT
WE WOULD RATHER
BE RUINED BY
PRAISE THAN SAVED
BY CRITICISM**

NORMAN VINCENT PEALE



Homolak, J. & Kodvanj, I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int. J. Antimicrob. Agents 56, 106044 (2020) doi:10.1016/j.ijantimicag.2020.106044.







An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19

Jan Homolak¹ · Ivan Kodvanj¹ · Vladimir Trkulja¹

Accepted: 23 January 2021 / Published online: 19 February 2021
© The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021



Poslan upit u HZZO
10.02.2021



*Poslan upit u HZZO
10.02.2021*

*Odgovor
HZZO-a
[24.02.2021.]*

Poštovani,

Hrvatski zavod za zdravstveno osiguranje (u dalnjem tekstu: Zavod) zaprimio je zahtjev za pristup informacijama gospodina Ivana Kodvanja, a kojim zahtjevom su zatraženi podaci vezani za istraživanje bolesti uzrokovane virusom SARS-CoV-2.

Zavod ne raspolaže traženim podacima.

Člankom 130. stavkom 1. točkom 17. Zakona o zdravstvenoj zaštiti („Narodne novine“, broj 100/18. i 125/19.) propisano je kako Hrvatski zavod za javno zdravstvo provodi kontinuirano epidemiološko praćenje, sprječavanje i suzbijanje zaraznih bolesti, uključujući koordiniranje i provođenje sustava javnozdravstvene pripravnosti.

Slijedom navedenog, u skladu sa člankom 21. stavkom 1. Zakona o pravu na pristup informacijama („Narodne novine“, broj 25/13. i 85/15.) ustupamo Vam zahtjev gospodina Ivana Kodvanja na nadležno postupanje.

O istom se obavještava i korisnik prava.

S poštovanjem,

Zamjenik službenika za informiranje



Hrvatski
zavod za
zdravstveno
osiguranje

Croatian
Health
Insurance
Fund

Direkcija
Marmontova 3, 10 000 Zagreb
+385 1 4005 000
+385 1 4005 033
+385 1 4012 609
+385 1 4006 485
[www.hzoo.hr](http://hzoo.hr)

KLASA: 008-0121-0108
URROJ: 338-01-02-06-21-02
Zagreb: 24. veljače 2021. godine

HRVATSKI ZAVOD ZA JAVNO
ZDRAVSTVO
10000 Zagreb
Rockefellerova 7
n/p službenik za informiranje

PREDMET: Ivan Kodvanj – podaci vezani za bolest uzrokovane virusom SARS-CoV-2.
– ustupanje zahtjeva

Poštovani,

Hrvatski zavod za zdravstveno osiguranje (u dalnjem tekstu: Zavod) zaprimio je zahtjev za pristup informacijama gospodina Ivana Kodvanja a kojim zahtjevom su zatraženi podaci vezani za istraživanje bolesti uzrokovane virusom SARS-CoV-2.

Zahtjev je prema člankom 130. stavkom 1. točkom 17. Zakona o zdravstvenoj zaštiti („Narodne novine“, broj 100/18. i 125/19.) propisano je kako Hrvatski zavod za javno zdravstvo provodi kontinuirano epidemiološko praćenje, sprječavanje i suzbijanje zaraznih bolesti, uključujući koordiniranje i provođenje sustava javnozdravstvene pripravnosti.

Slijedom navedenog, u skladu sa člankom 21. stavkom 1. Zakona o pravu na pristup informacijama („Narodne novine“, broj 25/13. i 85/15.) ustupamo Vam zahtjev gospodina Ivana Kodvanja na nadležno postupanje.

O istom se obavještava i korisnik prava.

S poštovanjem,



Zamjenik službenika za informiranje
Andrija Hemerle, RHP, Iur


O tome obavijest:
Ivan Kodvanj, Ivan.Kodvan@gmail.com


Upisa pramici: preporučeni a povratnicom

Hrvatski zavod za zdravstveno osiguranje
Marmontova 3, 10000 Zagreb
010-52958272670

Ustavno je ustavne u. nadležno registrirano u Zagrebu, MZB: 090427347
Rezponzibilan u Zagrebu, MZB: 090427347
Raspredjelj. Lucija Vlaović, Dr.med.spc.









Poštovani,


u vezi Vašeg zahtjeva za pristup informacijama od 01.04.2021. godine,
obavještavamo Vas sljedeće.

kako bi se osigurala potpunost i točnost tražene informacije obavještavamo
Vas kako u skladu s člankom 22. stavkom 1. točkom 3. Zakona o pravu
na pristup informacijama („Narodne novine“, broj 25/13. i 85/15.) produžujemo rok
za ostvarivanje prava na pristup informaciji za 15 dana od dana kada je trebalo
odlučiti o Vašem zahtjevu.

S poštovanjem,







Poštovani,

osobno se ispričavam na nejavljanju i proteku vremena. Kao zamjenik službenika za informiranje čekao sam odgovor nadležnih Službi Hrvatskog zavoda za zdravstveno osiguranje (u dalnjem tekstu: Zavod) u vezi Vašeg zahtjeva za pristup informacijama.

Tražene podatke Zavod nema u posjedu.

Sukladno odredbama Zakona o pravu na pristup informacijama, o navedenome biti će Vam dostavljeno Rješenje, a na koje će te moći izjaviti žalbu, sukladno uputi o pravnom lijeku.

S poštovanjem,

Poslan upit u HZZO
10.02.2021.

Odgovor HZZO
a [24.02.2021.]
Kontaktiran HZZO
(bez odgovora
do danas)
Osobni posjet
HZZZ
→ preusmjerili
na HZZO

Odgovor HZZO
[20.04.2021.]
Nema odgovora
šaljemo podsignatnik
[18.05.2021.]
Nema odgovora
šaljemo podsignatnik
[07.06.2021.]
Odgovori!!!
[08.06.2021.]



Sveučilište u Zagrebu
Medicinski fakultet
Središnja medicinska knjižnica

2021 MICC
Medical Information Conference Croatia

Wolters Kluwer
Health

Ovid

PITANJA ... I JOŠ VAŽNIJE – RJEŠENJA?



@JanHomolak
homolakjan@gmail.com

